Haplo-HSCT became feasible in the 1990s by intensifying the conditioning regimen to prevent graft rejection, and by the infusion of “megadoses” of CD34+ purified cells, thus depleting T cells responsible of the occurrence of graft-versus-host disease (GvHD) [2]. The gene discussed is CD34; the disease is graft versus host disease.